KO-947
CAS No. 1695533-89-1
KO-947 ( KO 947 | KO947 )
产品货号. M12583 CAS No. 1695533-89-1
KO-947 是一种在生化、细胞和体内抗肿瘤活性测定中有效的选择性 ERK1/2 激酶抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥1444 | 有现货 |
|
| 10MG | ¥2166 | 有现货 |
|
| 25MG | ¥3618 | 有现货 |
|
| 50MG | ¥5069 | 有现货 |
|
| 100MG | ¥6867 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称KO-947
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述KO-947 是一种在生化、细胞和体内抗肿瘤活性测定中有效的选择性 ERK1/2 激酶抑制剂。
-
产品描述KO-947 is a potent and selective inhibitor of ERK1/2 kinase in biochemical, cellular and in vivo antitumor activity assays; blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at low nanomolar concentrations.Solid Tumors Phase 1 Clinical(In Vitro):KO-947 is a 10 nM inhibitor of ERK with at least 50-fold selectivity against a panel of 450 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at low nanomolar concentrations.(In Vivo):In cell-line derived xenograft studies, KO-947 profoundly suppresses ERK signaling for up to five days after a single dose and induces regressions in RAS- and RAF-mutant melanoma, NSCLC and pancreatic cancer models on administration schedules ranging from daily to weekly. Intermittent dosing enables comparable antitumor activity at reduced dose-intensity.
-
体外实验KO-947 is a 10 nM inhibitor of ERK with at least 50-fold selectivity against a panel of 450 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling, including mutations in BRAF, NRAS or KRAS, at low nanomolar concentrations.
-
体内实验In cell-line derived xenograft studies, KO-947 profoundly suppresses ERK signaling for up to five days after a single dose and induces regressions in RAS- and RAF-mutant melanoma, NSCLC and pancreatic cancer models on administration schedules ranging from daily to weekly. Intermittent dosing enables comparable antitumor activity at reduced dose-intensity.
-
同义词KO 947 | KO947
-
通路MAPK/ERK Signaling
-
靶点ERK
-
受体ERK
-
研究领域Cancer
-
适应症Solid Tumors
化学信息
-
CAS Number1695533-89-1
-
分子量355.401
-
分子式C21H17N5O
-
纯度>98% (HPLC)
-
溶解度DMSO : 62.5 mg/mL 175.86 mM
-
SMILESO=C1NC2=CC(NN=C3C4=CC=NC=C4)=C3C=C2CN1CC5=CC=CC=C5
-
化学全称6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Patritumab
Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用,可有效抑制 EGFR,HER2,HER3,ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis),也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。
-
ERK5-IN-6
ERK5-IN-6 (compound 5J)是一种具有抗癌活性的 ERK5 激酶抑制剂。ERK5-IN-6 对 A549 细胞表现出良好的抗增殖活性,IC50 值为 4.56 μg/mL。
-
ML-191
ML-191 是 LPI 诱导的 ERK1/2 磷酸化的抑制剂。
021-51111890
购物车()
sales@molnova.cn

